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Acral melanomas (AM) is a distinct subtype of melanoma affecting the palms, soles and nail 
apparatuses. It is mostly identical to acral lentiginous melanoma according to Clark’s 
classification (Clark et al., 1986), but it may also include nodular melanoma and superficial 
spreading melanoma that developed on glabrous skin and nail apparatus (Curtin et al., 
2005). While AM is the least frequent subtype of cutaneous melanoma overall in Caucasians, 
it is the most prevalent type of melanoma in people of color. Prognosis of AM is generally 
poor, which may be in part due to delay in diagnosis (Bradford et al., 2009).  
The distinct histological and phenotypic characteristics suggest that AM might differ 
biologically from other types of cutaneous melanomas. Recent molecular genetic studies 
characterized AM as a unique type of melanoma showing higher frequency of chromosomal 
aberrations, especially focused amplifications of particular chromosome regions (Bastian et 
al., 2000; Curtin et al., 2005). Furthermore, recent discovery of frequent mutation or 
amplification of   gene in AM and mucosal melanoma has led to the molecular targeted 
therapy by approved drugs targeting KIT, such as imatinib, for advanced cases (Curtin et 
al., 2006). This would represent a first decisive step toward the individualized treatment of 
melanoma (Garrido &Bastian, 2010)  
	
Although AM accounts for 5% of all melanomas in the United States (Markovic et al., 
2007)(Table 1), it is a predominant form of melanoma in individuals with darker skin (ie, 
Blacks, Asians and Hispanics) (Cormier et al., 2006). The proportion of AM among all 
melanoma subtypes is greatest in blacks followed by Asians/Pacific islanders and Hispanic 
whites (Bradford et al., 2009). The nation:wide survey in Japan shows that AM accounts for 
41% of all melanomas (Ishihara et al., 2008)(Table 1), the rate being almost the same in Chinese 
(Chi et al., 2011). However, the absolute incidence of AM in darker:skinned individuals is 
similar to that in whites (Stevens et al., 1990; Bradford et al., 2009), who have a much higher 
incidence of melanoma overall due to the strong susceptibility to sunlight (Cormier et al., 
2006). Thus, carcinogens other than ultraviolet light (UVL) equally affecting all ethnic groups 
or endogenous mutagenesis may play a role in the development of AM. Trauma may have a 
role in AM development, since 13% to 25% of patients with AM reported prelesional trauma, 
such as puncture wounds, friction blisters and stone bruises (Coleman et al., 1980; Phan et al., 
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2006). The mean age at diagnosis of AM is 62.8 years, compared with 58.5 years for cutaneous 
melanoma overall. Incidence of AM significantly increases with each year of advancing age, 
which is seen across the different racial groups (Bradford et al., 2009). 
 
Type of 
Melanoma1) 
United States 
(Markovic et al., 2007) 
Japan 
(Ishihara et al., 2008) 
SSM 70% 17% 
NM 5% 20% 
LMM 4~15% 7% 
ALM 5% 41% 
Unknown 5~11% 13% 
1)SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo maligna melanoma; 
ALM, acral lentiginous melanoma 
Table 1. Comparison of melanoma types between the United States and Japan. 
Although acral volar skin and nail beds constitutes only a few % of skin surface, the fact that 
nearly half of cutaneous melanomas arise on these anatomical sites in darker:skinned 
individuals indicates that these are predilection sites of melanomas not causally related to 
UVL exposure. The melanocyte density in palmoplantar skin is five times lower than that 
found in nonpalmoplantar sites. Furthermore, the growth and differentiation of palmoplantar 
melanocytes are suppressed by dickkopf 1 (DKK1) secreted from dermal fibroblasts through 
the down:regulation of microphthalmia:associated transcription factor (MITF) and beta:
catenin (Yamaguchi et al., 2004). The reason why such growth:suppressed melanocytes in 
palmoplantar skin are more susceptible to melanoma development is currently unknown.  

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Clinically, AMs on palms and soles begin with irregularly pigmented macular lesions. The soles 
of the feet are most commonly involved. Morphological characteristics of early AM lesions 
include variable shades of brown from tan to black color, irregular and asymmetric shape often 
accompanied by notching at the periphery, and over 7mm in diameter (Saida, 1989) (Fig. 1a).  
 
        
Fig. 1. Clinical pictures of radial growth phase (a) and tumorgenic vertical growth phase  
(b) of AM. 
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Fig. 2. Dermoscopy of early AM (a) and melanocytic nevus on acral volar skin (b, c, and d).  
a, palarelle ridge pattern; b, pararelle furrow pattern; c, lattice:like pattern; d, fibrillar pattern. 
Dermoscopic observations of these early lesions show band:like pigmentation on ridges of 
the skin markings, designated as a “parallel ridge pattern”(Fig. 2a). This is in sharp contrast 
to the dermoscopic patterns in acral melanocytic nevi, which show parallel linear 
pigmentation along the sulci of the skin markings, designated as a “parallel furrow 
pattern”(Fig. 2b) and its variants “lattice:like pattern“ (Fig. 2c) and “fibrillar pattern”(Fig. 
2d) (Oguchi et al., 1998; Miyazaki et al., 2005). The sensitivity and specificity of the parallel 
ridge pattern in diagnosing early AM is 86% and 99%, respectively (Saida et al., 2004). A 
simple three:step algorism effectively discriminating early AM from acral melanocytic nevi 
has been proposed (Fig. 3) (Saida et al., 2011). This algorism classifies acquired pigmented 
lesions on acral volar skin by the dermoscopic findings and the maximal diameter, and 
recommends three management options including “no need to follow:up”, “periodic follow:
up”, and “excision of the lesion for histopathological evaluation”. 
In contrast to the palmoplantar melanoma, nail apparatus melanoma more often affects 
fingers than the toes. The digits most commonly affected are the thumb followed by the 
great toe. If the AM is situated in the nail matrix, a longitudinal pigmented band of the nail 
plate is the earliest sign (Fig. 4a). As melanocytic nevi of the nail matrix also typically 
accompany longitudinal melanonychia, identifying early nail matrix melanoma is 
challenging. Dermoscopy again provides useful information for this differentiation. The 
suspicious dermoscopic features of early nail matrix melanoma are irregular lines on a 
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brown background, pigmentation of the cuticle (micro:Hutchingson’s sign), a wide 
pigmented band, and triangular pigmentation on the nail plate (Fig. 4b) (Koga et al., 2011). 
 
 	
	  
!"	


	 

!
	



生検して病理組織学的に検討
		
	
	
	

		

 
#	$%$&&$
%$'
	
≦(
!

)"
 
	
 
$	


	
*(
$		
)"
		
	
+
	
 
Fig. 3. Three:step algorism for the management of acquired pigmented lesions on plams and 
soles (Adapted from Saida et al., 2011, with permision). 
 
             
Fig. 4. Clinical (a) and dermoscopic (b) photographs of early nail matrix melanoma. The 
arrow indicates micro:Hutchingson‘s sign. 
 !
www.intechopen.com

				
	
	
	

(
The tumorigenic vertical growth phase of palmoplantar melanoma is characterized by the 
development of a nodule often associated with ulceration (Fig. 1b). The development of a 
subungal tumor and the destruction of the nail plate are observed in the vertical growth 
phase of nail apparatus melanoma. 
"#
Histopathology of the earliest lesions of palmoplantar melanoma shows proliferation of 
solitary arranged slightly atypical melanocytes mainly detected in the crista profunda 
intermedia, the epidermal rete ridge underlying the ridges of the skin markings (Ishihara et 
al., 2006). In early nail apparatus melanoma, slightly atypical melanocytes proliferate in the 
epidermis of nail matrix. Eventually, large atypical melanocytes, frequently with prominent 
pigmented dendrites, proliferate as single cells in the basal layer of the hyperplastic 
epidermis while some tumor cells can be found in the upper layer of the epidermis. Nesting 
of melanocytes is not prominent, and tends to occur at the tips of the rete ridges. Brisk 
lichenoid lymphocytic infiltrate that may obscure the dermal:epidermal junction is common. 
In the vertical growth phase, atypical tumor cells are often spindle:shaped. Desmoplastic 
change is not uncommon (Clark et al., 1986).  
$		
	
There exists clinical heterogeneity in cutaneous melanoma with different susceptibility to 
UVL, which may be explained by differences in somatic genetic changes. Recent molecular 
genetic investigations have revealed that melanomas from intermittently sun:exposed skin, 
most of which are located on trunk and extremities, show frequent mutations in either !"#$ 
or %"# gene. In contrast, !"#$	or	%"# mutations are rather infrequent in melanomas 
arising from sun:protected areas, such as acral skin, nail apparatus and mucosa (Table 2). 
Instead, these types of melanomas show a higher degree of chromosomal aberrations; 
specifically, genomic amplifications involving small portions of chromosome arms (Curtin 
et al., 2005). In AM, the most frequently amplified region is chromosome 11q13 which 
contains the 	& gene. Narrow amplifications of other chromosome regions, including 
4q12, 5p15, 11q14 and 22q11:13, are also found (Bastian et al., 2000). Target genes of 4q12 
and 11q14 amplifications appear to be	   and	 '#!(, respectively (Curtin et al., 2006; 
Chernoff et al., 2009).  
 
 Acral melanomas 
Melanomas from 
intermittently sun:
exposed skin 
Reference 
!"#$	 23% mutated 59% mutated (Curtin et al., 2005) 
%"#	 10% mutated 22% mutated (Curtin et al., 2005) 
 	
14% mutated 
24% amplified 
0% mutated 
0% amplified 
(Curtin et al., 2006) 
)	&	 44% amplified 5% amplified (Sauter et al., 2002) 
'#!(	 19% amplified 3% amplifieda (Chernoff et al., 2009) 
a including one melanoma on face 
Table 2. Comparison of somatic genetic changes between acral melanomas and melanomas 
from intermittently sun:exposed skin. 
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Cyclin D1	 positively regulates the activity of cyclin dependent kinases, leading to 
phosphorylation of retinoblastoma protein promoting entry into mitosis, and acts as an 
oncogene (reviewed in (Tashiro et al., 2007)). Interestingly, while gene amplifications are 
usually found in association with disease progression in other cancers, 	 & gene 
amplifications in AM are detected early in the radial growth phase (Bastian et al., 2000). 
Furthermore, copy number increase of 	& gene was observed even in normal:looking 
melanocytes in the epidermis beyond the histopathologically recognizable margin of 
melanoma (Bastian et al., 2000; North et al., 2008), as well as in very early acral melanoma 	
 lesions, which shows slight increase of non:atypical melanocytes in the basal cell layer of 
the epidermis (Yamaura et al., 2005). These genetically aberrant cells with normal morphology 
are “ field cells” (Bastian, 2003), which represent a latent progression phase that precedes the 
stage of atypical melanocyte proliferation in the epidermis. These observations suggest that 
amplification of the 	& gene might be one of the earliest events in AM development. The 
presence of amplifications, however, indicates that other aberrations likely cause genomic 
instability (North et al., 2008). Investigations in a radial growth phase AM cell line SMYM:
PRGP harboring 	 &	 amplification (Fig. 5) suggest that overly expressed cyclin D1 
protein may act as a survival factor (Murata et al., 2007).	While	the progressive increase of the 
	&	copy number from normal:looking melanocytes to the 	 portion to the invasive 
melanoma was observed, suggesting that the increased 	&	gene dosage confers a growth 
advantage during later stages of tumor progression (North et al., 2008), this may simply reflect 
the increase of genomic instability associated with melanoma progression (Takata et al., 2010). 
 
 
Fig. 5. Amplification of the 	& gene in radial growth phase acral melanoma cell line 
SMYM:PRGP (Murata et al., 2007). Green signals, chromosome 11 centromere; red signals, 
	&. 
While mutations of the !"#$ and %"# genes are infrequent in AM, a substantial number 
of AM harbor mutations or amplifications of the  	 gene encoding a receptor tyrosine 
kinase (Curtin et al., 2006). Recent studies have revealed   mutations and amplification in 
14% and 24% of AMs, respectively (Table 2) (Woodman &Davies, 2010). About 30% of the 
tumors with   mutations also show increased copy number/amplification of  . The 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mutations identified in AM differ from those found in gastrointestinal stromal tumors 
(GIST). The majority of   mutations in GIST are deletions or insertions, whereas those 
found in melanoma are substitution mutations. In addition,   mutations are not present in 
exon 9, which is the location of 15% of   mutations in GIST. More than half of   
mutations in melanoma are found in exon 11, which encodes juxtamembrane domain of KIT 
receptor, whereas mutations are also found in exons 13, 17 and 18 encoding kinase domains 
(Woodman &Davies, 2010).  
GAB2 is a scaffolding protein that mediates interactions with various signaling pathways 
including RAS:RAF:ERK and PI3K:AKT signaling, and is a critical molecule for melanoma 
progression (Horst et al., 2009). A recent study found '#!( amplification in 5 of 23 (19%) 
AMs, while amplifications were rare in other types of cutaneous melanomas (Table 2). The 
majority of '#!( amplification occurred independent from genetic alterations in	!"#$	%"#	
 	and 	&, suggesting a critical role of '#!( in a subset of AM (Chernoff et al., 2009).  
%				
Since	   mutations are detected in ~15% of AM, KIT is a promising molecular target of 
metastatic AM. Several	 	 
 experiments using melanoma cell lines harboring   
mutations have actually shown significant growth suppressive effects of small molecular 
KIT inhibitors, such as imatinib, which are already approved for other cancers. Imatinib 
dramatically decreased proliferation, and was cytotoxic to a mucosal melanoma cell line 
demonstrating a highly amplified	   exon 11 V559D mutation (Jiang et al., 2008). In 
contrast, cell viability of another melanoma cell line with   exon 11 L576P mutation, the 
most common   mutation in melanoma (34%) (Woodman &Davies, 2010), was not 
reduced by imatinib. However, dasatinib reduced cell viability of this cell line at 
concentrations as low as 10nM. Molecular modeling studies found that the L576P mutation 
induces structural changes in KIT that reduce the affinity for imatinib but not for dasatinib 
(Woodman et al., 2009). An acral melanoma cell line with non:amplified	  exon 17 D820Y 
was also resistant to imatinib treatment. The   D820Y mutation usually arises as a 
secondary mutation in the setting of imatinib treatment in GIST, which was shown to be 
sensitive to sunitinib. As expected, treatment of the   D820Y cell line with 1 KM of 
sunitinib showed modest reduction in cell proliferation. (Ashida et al., 2009). 
Clinically, dramatic response to imatinib therapy has been observed in several sporadic 
cases with metastatic acral and mucosal melanomas with   mutations, such as exon 13 
K642E, 7:codon duplication in exon 11, and exon 11 V599A (Hodi et al., 2008; Lutzky et al., 
2008; Terheyden et al., 2010). However, gene amplification and overexpression of wild:type	
 , which is frequently present in acral and mucosal melanomas (Woodman &Davies, 
2010), did not translate into clinical efficacy of imatinib (Hofmann et al., 2009). Consistent 
with an	 	
 study, metastatic melanoma patients with the   L576P mutation showed 
marked reduction (>50%) and elimination of tumor F18:fluorodeoxyglucose (FDG):avidity 
by positron emission tomography(PET) imaging after dasatinib treatment (Woodman 
&Davies, 2010). Partial response by dasatinib was also observed in a patient with the   
exon 13 K642E mutation (Kluger et al., 2010). 
Three phase:II trials of imatinib in unselected metastatic melanomas were mostly 
disappointing, and highlighted the importance of proper patient selection (Ugurel et al., 
2005; Wyman et al., 2006; Kim et al., 2008). There are currently three ongoing clinical trials 
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prospectively testing imatinib in selected patients with melanoma showing	  mutations or 
amplifications (mostly acral and mucosal melanomas)(Table 3). The NCT00470470 trial 
selected stage III or IV patients with somatic mutations in  . Of the 12 evaluable patients, 
2 demonstrated a complete response. Of note, these two patients had both amplification and 
mutation of  . A partial response was observed in two patients. All but two, who had 
mutations known to be resistant to imatinib in GIST, of the remaining patients had stable 
disease (Carvajal et al., 2009). In another phase:II trial of imatinib in patients with advanced 
melanoma from acral skin, mucosa or chronically sun:damaged skin (NCT00424515), five of 
ten patients with   mutations demonstrated a partial response. In contrast, none of the ten 
patients who had wild:type/amplified   showed a clinical response (Fisher et al., 2010). 
In the NCT00881049 trial which recruited Chinese patients with metastatic melanoma 
harboring   aberrations, a rate of 20% partial response and 40% stable disease was 
achieved, with 60% overall disease control rate (Guo et al., 2010). These results show clinical 
benefit of imatinib in a proportion of molecularly selected patients. 
 
 Phase NCT number   aberrations required for eligibility 
Imatinib 2 00470470 Mutation or amplification 
Imatinib 2 00424515 Mutation or amplification 
Imatinib 2 00881049 Mutation or amplification 
Imatinib and 
temozolomide 
1/2 00667953 Mutation 
Nilotinib 2 00788775 Mutation or amplification 
Nilotinib and 
dacarbazine 
3 01028222 Mutation 
Sunitinib 2 00631618 Mutation or amplification 
Sunitinib 2 00577382 None 
Dasatinib 2 00700882 None 
Dasatinib and 
dacarbazine 
1/2 00597038 None 
Table 3. Clinical trials of KIT inhibitors for melanoma (Modified from Romano et al., 2011). 
Nilotinib is a second:generation tyrosine kinase inhibitor of KIT, PDGFR and BCR:ABL. 
Nilotinib is potent as imatinib against mutant  , and is significantly more potent than 
imatinib against wild:type  . A phase:II trial of nilotinib in patients with melanoma 
characterized by a   mutation or amplification is ongoing, and a randomized phase:III, 
open:label study to compare the efficacy of nilotinib versus dacarbazine for treatment of 
patients with metastatic melanoma harboring a   mutation has been initiated. Phase:II 
trials testing other tyrosine kinase inhibitors targeting KIT, such as sunitinib and dasatinib, 
for melanoma are also ongoing (Table 3).   
&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It is now clear that melanoma arises from multiple pathways, with initiating and promoting 
factors differing for each. Melanomas on intermittently sun:exposed skin preferentially affect 
Caucasians who have an inherently high propensity for melanocyte proliferation characterized 
by high nevus counts (Whiteman et al., 2003). Exposure to intense bursts of UVL radiation, 
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especially in childhood, is the major risk factor. This type of melanomas may arise from pre:
existing melanocytic nevus, and the mutation of the !"#$	 gene may be a key initiating 
somatic genetic event (Michaloglou et al., 2008). By contrast, AM arises 	

, and equally 
affects all ethnic groups. The first genetic aberration affecting normal melanocytes in acral 
volar skin would be one that disrupts the maintenance of genomic integrity. This would lead 
to the amplification of 	&	and the selection for clonal expansion of affected melanocytes. 
Then, acquiring activating mutations in oncogenes, such as   (Curtin et al., 2006), may be a 
crucial step inducing proliferation of transformed melanocytes (Takata et al., 2010). 
Understanding molecular pathogenesis in different types of melanomas will lead to the 
development of effective prevention and treatment strategies for individual patients. 
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